Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple supplement make chemo work better for advanced colon cancer?

NCT ID NCT06509880

Disease control Sponsor: MIPO Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This trial investigates whether adding a dietary supplement called sodium nucleinate to standard FOLFOX chemotherapy helps people with metastatic colorectal cancer (cancer that has spread). Participants are randomly assigned to receive either the supplement or a placebo alongside four cycles of chemotherapy. Researchers track treatment completion, quality of life, and survival up to one year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sodium nucleinate (Adenorine)
What this could lead to
If it works, this could point toward a way to make chemotherapy more effective and improve daily life for people with advanced colorectal cancer.
What could go wrong
This is a mid-stage trial with 187 participants, so results may not apply to everyone. The supplement may not provide added benefit and could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

187 people

The number who actually took part.

Started

Jul 2022

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically confirmed colorectal cancer. 2. Locally advanced or metastatic disease as treated with palliative FOLFOX per protocol (including metastatic disease \[M1\]). 3. Able to receive FOLFOX chemotherapy and to comply with study procedures. 4. Provided written informed consent. Exclusion Criteria: 1. Active pulmonary tuberculosis. 2. Decompensated diabetes mellitus. 3. Decompensated cardiac, vascular, pulmonary, hepatic, or renal failure.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Monitoring, immunologic

Contacts and locations

Locations

  • MIPOClinic

    Almaty, Almaty, 050038, Kazakhstan

More trials for these conditions

Other studies related to the condition(s) this trial covers.